不久前，我们发布了一篇文章《MCP，媲美TCP/IP？》，反响较好。其中，有一个读者的留言，启发了我们： MCP协议、Agent协作、能力注册，AI Agent大潮来袭，普通人如何"上车"？ 是啊，在这样一个快速变化的时代，普通人要怎么做，才能不被甩下时代的列车呢？ 大模型爆火之后，Prompt成了AI圈的"香饽饽"。 人人都在学提示词技巧，调教DeepSeek、ChatGPT、掌握LangChain、写出像样的函数调用结构，成了AI从业者的新标配。无论是运营、产品、工程师还 是自由职业者，都在追赶这波热潮。 但你是否也开始察觉——焦虑感，正在悄悄蔓延。 "我学了这么多Prompt技巧，怎么感觉用处越来越有限？" | : 突™ 山东 1小时间 | | --- | | " 普通AI行业从业者在这个变革中从何处入口以便后期能更加适配行业工作? 如果现在不学习 | | Prompt技巧，不明确相关任务流程，是否会正式来临面临落伍。 | | 现在学习的这些搭建技巧能否适配后期行业内容? | | 底层普通AI从业人员，好比现在的基础IT运维人员现在应该从哪些方面的技术去做学习铺垫? | | 作者赞过 | "LangCh ...

Latham Group (SWIM) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Casey Kotary - DirectorScott Rajeski - President & Chief Executive OfficerOliver Gloe - Chief Financial OfficerRyan Merkel - Co-Group Head–IndustrialsW. Andrew Carter - Vice PresidentAnika Dholakia - AVP - Equity ResearchSean Callan - Community Relations Manager Conference Call Participants Robert Schultz - AnalystGreg Palm - Senior Research Analyst Operator Good day, and welcome to the Latham Group Inc. First Quarter tw ...

Latham Group (SWIM) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Casey Kotary - DirectorScott Rajeski - President & Chief Executive OfficerOliver Gloe - Chief Financial OfficerRyan Merkel - Co-Group Head–IndustrialsW. Andrew Carter - Vice PresidentAnika Dholakia - AVP - Equity ResearchSean Callan - Community Relations Manager Conference Call Participants Robert Schultz - AnalystGreg Palm - Senior Research Analyst Operator Good day, and welcome to the Latham Group Inc. First Quarter tw ...

Latham Group (SWIM) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Latham Group Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press then 1 on your touch tone phone. To withdraw your question, please press then 2. Please note this event is being recorded. I would now like to turn the conference over to Ms. C ...

First Quarter 2025 Financial Highlights: LATHAM, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced financial results for the first quarter 2025 ended March 29, 2025. Commenting on the results, Scott Rajeski, President and CEO, said, "Our first quarter results were in line with our expectations and reflected the relative strength of Lat ...

Core Insights - SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) with a pharmacokinetic profile supporting a potential best-in-class status [1][3] - The company plans to initiate a Phase 2 trial in mid-2025, which will include SPY001 and other candidates, with initial data expected in 2026 [1][2] Group 1: SPY001 Development - SPY001 has shown a human half-life of approximately 80 days, which is more than three times that of vedolizumab, allowing for potential quarterly or biannual dosing [3][4] - Interim data from the Phase 1 trial indicates that SPY001 is well tolerated and maintains target engagement at expected Phase 2 trough concentrations [4] Group 2: Clinical Trials and Future Plans - The Phase 2 platform trial will test SPY001 as a monotherapy and in combination with other therapies for ulcerative colitis patients, expected to begin mid-2025 [2][3] - Initial monotherapy data from the Phase 2 trial is anticipated in 2026 [1] Group 3: Preclinical and Clinical Data - Preclinical studies indicate that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis [4] - The pharmacodynamic data supports rapid and sustained saturation of α4β7 receptors with a single dose of SPY001 [1][4] Group 4: Company Overview - Spyre Therapeutics focuses on developing next-generation therapies for IBD and other immune-mediated diseases through advanced antibody engineering and therapeutic combinations [5] - The company's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 [5]

SINGAPORE, April 30, 2025 (GLOBE NEWSWIRE) -- INNEOVA Holdings Limited (Nasdaq: INEO, "INNEOVA Holdings" or the "Company" or the "Group"), a leading Singapore-based provider of high-quality Original Equipment Manufacturer ("OEM"), third-party branded and in-house branded replacement parts for motor vehicles and non-vehicle combustion engines, today announced that it has completed the acquisition of INNEOVA Engineering Pte. Ltd. ("INNEOVA Engineering"), a Singapore-based engineering solutions provider. This ...

【CNMO科技消息】水泥是现代建筑不可或缺的材料，但其生产过程却带来了巨大的环境负担——全球 约8%的二氧化碳排放源自水泥制造。为了寻找更加环保的替代方案，美国蒙大拿州立大学的工程师们 开发出了一种基于真菌的新型混凝土替代材料，为可持续建筑带来了新的希望。 这项创新成果属于工程活性材料（ELMs）领域，即将活体生物与非生物材料结合，创造出具有独特性 能的新型材料。此前，ELMs面临的最大挑战是寿命短暂，但蒙大拿州立大学的这款真菌混凝土替代品 能在至少四周内保持代谢活性，成为目前最持久的候选材料之一。 该材料的核心是快速生长的真菌Neurospora crassa，其形成的菌丝网络构建了坚固的骨架结构。研究人 员随后引入了一种名为Sporosarcina pasteurii的细菌，促使材料内部发生微生物诱导碳酸盐沉积 （MICP）过程，将原本松散的基材转变为类似水泥的坚固物质。 相关研究分析 更为关键的是，真菌骨架为内部结构设计提供了极高的自由度。研究团队模拟了人类皮质骨内部的复杂 几何结构，从而在保证强度和韧性的同时，为材料带来潜在的自愈合能力。这种灵活的架构设计，为未 来建筑材料的智能化和可持续性开辟了新方 ...

Xencor (XNCR) Update / Briefing April 29, 2025 05:00 PM ET Speaker0 Welcome to today's R and D call hosted by Xencor. At this time, all participants are in a listen only mode. After the speakers' presentation, we will conduct a question and answer session. I will now turn the call over to your host, Charles Lyles, Senior Director of Corporate Communications and Investor Relations. Speaker1 Thank you, and good afternoon. Earlier today, we issued a press release announcing positive interim results from our Ph ...

Core Insights - Kytopen Corp and Aldevron have entered a joint marketing agreement to enhance workflow solutions for cell therapy manufacturers by combining their technologies [1][6] - The collaboration focuses on promoting the synergies of Aldevron's Nanoplasmid™ vector technology and Kytopen's Flowfect Tx™ GMP cellular engineering platform for CRISPR-mediated engineering of primary T Cells [1][2] Technology Overview - Aldevron's Nanoplasmid vector technology offers high transgene expression and an improved safety profile, while Kytopen's Flowfect technology ensures gentle gene delivery with unlimited scalability [2][6] - The combination of these technologies results in an enhanced CRISPR-mediated T-cell engineering workflow, yielding high outputs and saving time for cell therapy developers [2][6] Upcoming Presentations - Kytopen will present a joint poster at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting from May 7-10, 2025, in New Orleans, showcasing data on increased yield and manufacturing ease compared to viral and electroporation technologies [3][6] - A Global Showcase Oral Presentation will also be held on May 8, 2025, highlighting a fully validated, non-viral GMP platform for engineered cell manufacture at clinical and commercial scales [5][6] Strategic Commitment - The collaboration reflects a shared commitment to advancing cell therapies by streamlining workflows to deliver higher yields of healthier cells [4] - The partnership aims to meet the growing patient demand as the adoption of CRISPR-based therapies accelerates [4]